Loading...
•
Dec 31, 2023
ResMed Q2 2024 Earnings Report
ResMed's Q2 2024 results announced, featuring revenue growth and decreased operating profit.
Key Takeaways
ResMed Inc. reported a 12% increase in revenue to $1.2 billion for the second quarter of fiscal year 2024. Diluted earnings per share were $1.42, and non-GAAP diluted earnings per share were $1.88. The company saw strong growth across its device, masks and accessories, and residential care software businesses.
Revenue increased by 12% to $1.2 billion.
Diluted earnings per share were reported at $1.42; non-GAAP diluted earnings per share at $1.88.
Income from operations decreased by 2%; non-GAAP operating profit increased by 20%.
The company resumed its share repurchase program, buying back $50 million worth of shares.
ResMed
ResMed
ResMed Revenue by Segment
ResMed Revenue by Geographic Location
Revenue by Segment
Total Devices Revenue
CapyFin.comTotal Masks and other Revenue
CapyFin.comResidential Care Software Revenue
CapyFin.comRevenue by Geographic Location
U.S., Canada, and Latin America Revenue
CapyFin.comEurope, Asia, and other markets Revenue
CapyFin.com Forward Guidance
ResMed is focusing on product innovation, operational excellence, and increasing brand awareness to improve 250 million lives in 2025.
Positive Outlook
- Expanding production and delivery of market-leading flow generator platforms.
- Successfully launching the latest generation platform, AirSense 11, into new markets and geographies.
- Strong growth in patient flow supports ongoing device growth.
- Augmented and accelerated replenishment programs for sustained mask and accessories growth.
- Organic growth of residential care software business is delivering and complementing core mask and accessory business growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income